ArticleProceedings of the National Academy of Sciences of the United States of America2026
The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion.
Mohamed I Khalil, Jie Wang, Lexi Vu, Canchai Yang, Congcong Yin, Smriti Chadha, Harrison Nabors, Daniel Vocelle, Danielle G May, Rachel J Chrisopulos and 7 more
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Mohamed I KhalilDepartment of Microbiology, Genetics, and Immunology, Michigan State University, East Lansing, MI 48824.ORCID 0000-0002-8331-1490
Jie Wang *Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, MI 48202.
Lexi Vu *Department of Microbiology, Genetics, and Immunology, Michigan State University, East Lansing, MI 48824.ORCID 0000-0001-9243-7469
Canchai Yang *Department of Microbiology, Genetics, and Immunology, Michigan State University, East Lansing, MI 48824.
Congcong YinCenter for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, MI 48202.ORCID 0000-0003-0865-2823
Smriti ChadhaDepartment of Microbiology, Genetics, and Immunology, Michigan State University, East Lansing, MI 48824.
Harrison NaborsDepartment of Microbiology, Genetics, and Immunology, Michigan State University, East Lansing, MI 48824.
Daniel VocelleDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824.
Danielle G MayEnabling Technologies, Sanford Research, Sioux Falls, SD 57104.
Rachel J ChrisopulosEnabling Technologies, Sanford Research, Sioux Falls, SD 57104.
Craig C WelbonCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104.ORCID 0000-0002-3134-0636
Li ZhouCenter for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, MI 48202.
William C SpanosCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104.
Matthew P BernardDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824.ORCID 0000-0002-5950-3580
Qing-Sheng MiCenter for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, MI 48202.ORCID 0000-0002-1411-6827
Dohun PyeonDepartment of Microbiology, Genetics, and Immunology, Michigan State University, East Lansing, MI 48824.ORCID 0000-0003-1970-844X
Funding
Yeast 2 HybridP20GM103620 · NIGMS · SANFORD RESEARCH/USD · PI ROUX, KYLE J · 2013 to 2023
$24.2M
Supplement for Google cloud build-outR24GM137786 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Alan Tackett · 2020 to 2026
$15.4M
Pilot Project ProgramP30GM145398 · NIGMS · SANFORD RESEARCH/USD · PI W KEITH MISKIMINS · 2023 to 2026
$6.2M
Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancerR01DE029524 · NIDCR · MICHIGAN STATE UNIVERSITY · PI PYEON, DOHUN, SPANOS, WILLIAM CHARLES · 2020 to 2024
$3.2M
Immune receptor degradation for immune evasion of head and neck cancerR01DE033797 · NIDCR · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · PI QING-SHENG MI, Dohun Pyeon · 2025 to 2026
$1.3M
Membrane Ubiquitin Ligase-Driven Immune Evasion in HPV+ Head and Neck CancerF31DE034281 · NIDCR · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · PI VU, LEXI · 2024 to 2025
$95k
Henry Ford + Michigan State University Health Sciences Integration GrantMichigan State University (MSU) Global Impact InitiativeMichigan State University (MSU) Strategic Partnership GrantNIDCR NIH HHS F31 DE034281NIDCR NIH HHS R01 DE029524NIDCR NIH HHS R01 DE033797NIGMS NIH HHS P20 GM103620NIGMS NIH HHS P30 GM145398NIGMS NIH HHS R24 GM137786
6 · The paper itself
Abstract
The loss of major histocompatibility complex class I (MHC-I) molecules has been proposed as a mechanism for cancer immune evasion. Nevertheless, the mechanism is poorly understood. We report here that membrane-associated RING-CH-type finger 8 (MARCHF8), upregulated by human papillomavirus (HPV), ubiquitinates and degrades MHC-I in HPV-positive head and neck cancer (HPV+ HNC). Inhibiting MARCHF8 restores MHC-I levels on HPV+ HNC cells, suppresses tumor growth, and increases the infiltration of natural killer (NK) and T cells in the tumor microenvironment. Furthermore,
Indexed as
Head and Neck NeoplasmsHistocompatibility Antigens Class IPapillomavirus InfectionsTumor EscapeUbiquitin-Protein LigasesAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHuman Papillomavirus VirusesHumansImmune EvasionKiller Cells, NaturalMiceMice, KnockoutTumor MicroenvironmentHistocompatibility Antigens Class IUbiquitin-Protein Ligaseshead and neck cancerhuman papillomavirusimmune evasionMARCHF8MHC-I
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion. · full record | OpenQuestion